Progestogens in endometrial cancer

Ido Laskov; Walter H. Gotlieb

doi:10.1007/978-3-319-14385-9_11

Progestogens in endometrial cancer

Ido Laskov, Walter H. Gotlieb^*

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Hysterectomy is the treatment choice for patients with endometrial cancer, but progesterone may be an acceptable option for young women who wish to preserve their fertility or for women with severe co-morbidities. Although progestin therapy of low-grade early-stage endometrial carcinoma has been utilized for years, many questions remain unanswered. Cohort studies show a high chance of disease regression (65–76 %) and encouraging live birth rates (28–35 %). The risk of disease relapse during follow-up is significant but overall outcome and survival are not jeopardized by well controlled temporary conservative treatment. Young women desiring to pursue this treatment need to undergo thorough counseling, extensive work-up, and close follow-up and should undergo hysterectomy once family planning is complete.

Original language	English
Title of host publication	Progestogens in Obstetrics and Gynecology
Publisher	Springer International Publishing
Pages	159-176
Number of pages	18
ISBN (Electronic)	9783319143859
ISBN (Print)	9783319143842
DOIs	https://doi.org/10.1007/978-3-319-14385-9_11
State	Published - 1 Jan 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-319-14385-9_11

Cite this

@inbook{0b82801bc7c14a7aa0b30bbda79fe9ac,

title = "Progestogens in endometrial cancer",

abstract = "Hysterectomy is the treatment choice for patients with endometrial cancer, but progesterone may be an acceptable option for young women who wish to preserve their fertility or for women with severe co-morbidities. Although progestin therapy of low-grade early-stage endometrial carcinoma has been utilized for years, many questions remain unanswered. Cohort studies show a high chance of disease regression (65–76 %) and encouraging live birth rates (28–35 %). The risk of disease relapse during follow-up is significant but overall outcome and survival are not jeopardized by well controlled temporary conservative treatment. Young women desiring to pursue this treatment need to undergo thorough counseling, extensive work-up, and close follow-up and should undergo hysterectomy once family planning is complete.",

author = "Ido Laskov and Gotlieb, {Walter H.}",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-14385-9_11",

language = "אנגלית",

isbn = "9783319143842",

pages = "159--176",

booktitle = "Progestogens in Obstetrics and Gynecology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Progestogens in endometrial cancer

AU - Laskov, Ido

AU - Gotlieb, Walter H.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Hysterectomy is the treatment choice for patients with endometrial cancer, but progesterone may be an acceptable option for young women who wish to preserve their fertility or for women with severe co-morbidities. Although progestin therapy of low-grade early-stage endometrial carcinoma has been utilized for years, many questions remain unanswered. Cohort studies show a high chance of disease regression (65–76 %) and encouraging live birth rates (28–35 %). The risk of disease relapse during follow-up is significant but overall outcome and survival are not jeopardized by well controlled temporary conservative treatment. Young women desiring to pursue this treatment need to undergo thorough counseling, extensive work-up, and close follow-up and should undergo hysterectomy once family planning is complete.

AB - Hysterectomy is the treatment choice for patients with endometrial cancer, but progesterone may be an acceptable option for young women who wish to preserve their fertility or for women with severe co-morbidities. Although progestin therapy of low-grade early-stage endometrial carcinoma has been utilized for years, many questions remain unanswered. Cohort studies show a high chance of disease regression (65–76 %) and encouraging live birth rates (28–35 %). The risk of disease relapse during follow-up is significant but overall outcome and survival are not jeopardized by well controlled temporary conservative treatment. Young women desiring to pursue this treatment need to undergo thorough counseling, extensive work-up, and close follow-up and should undergo hysterectomy once family planning is complete.

UR - http://www.scopus.com/inward/record.url?scp=84943762387&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-14385-9_11

DO - 10.1007/978-3-319-14385-9_11

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:84943762387

SN - 9783319143842

SP - 159

EP - 176

BT - Progestogens in Obstetrics and Gynecology

PB - Springer International Publishing

ER -

Progestogens in endometrial cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this